19:48 , May 3, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 22 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in Europe; premarket on U.S. exchange; (B) Fiscal 4Q; Company Date Pre/post mkt 1Q19...
21:59 , Apr 25, 2019 |  BC Extra  |  Company News

Salix licenses S1P receptor modulator from Mitsubishi

Mitsubishi has found a new partner for its oral S1P receptor modulator in Salix, two years after Biogen decided to return its rights to the compound. Salix Pharmaceuticals Ltd. gained exclusive rights Thursday to develop...
20:06 , Apr 24, 2019 |  BC Extra  |  Financial News

Why Satsuma investors see room for another migraine therapy

While a new class of drugs has captured most of the attention around migraine treatments, Satsuma's investors believe there's room in the marketplace for a new formulation of an old drug. Satsuma Pharmaceuticals Inc. (South...
21:31 , Apr 1, 2019 |  BC Extra  |  Company News

Salix licenses new NASH target from UCLA

Salix is entering the NASH and NAFLD race with a license from UCLA to a compound against a new target in the space. Salix Pharmaceuticals Ltd. gained a license to develop and commercialize a fusion...
19:33 , Mar 1, 2019 |  BC Week In Review  |  Company News

Bausch wins $195M bid to acquire bankrupt Synergy's assets

Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC) won a $195 million bid to acquire assets of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) in a court-supervised bankruptcy auction. Synergy markets gastrointestinal drug Trulance plecanatide. Trulance is an uroguanylin analog...
00:04 , Feb 16, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck Company Date Pre/post mkt 4Q18 EPS est 4Q17 EPS Expected chg NeoGenomics Inc. (NASDAQ:NEO) 2/19 Pre $0.05 $0.05 0% Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC) 2/20 Pre $0.84 $0.98 -14% Genmab A/S...
19:52 , Jan 17, 2019 |  BioCentury  |  Regulation

Products on shutdown standby

Products on shutdown standby On Jan. 14, FDA said it has reserves to continue drug reviews for five more weeks if the government shutdown continues. There are at least six PDUFA dates for new products...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...